12 results on '"Peters, Natascha A.J.B."'
Number of results to display per page
Search Results
2. Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS)
- Author
-
Beerepoot, Laurens V., Creemers, Geert-Jan, van Cruijsen, Hester, de Groot, Jan Willem B., van Halteren, Henk K., Helgason, Helgi H., Hendriks, Mathijs P., Hoekstra, Ronald, van Huis-Tanja, Lieke H., Kapiteijn, Ellen, Los, Maartje, van Meerten, Esther, Peters, Natascha A.J.B., Pruijt, Johannes F.M., van Ufford-Mannesse, Patricia Quarles, Sie, Mark P.S., Sommeijer, Dirkje W., Spierings, Leontine E.A.M.M., Terheggen, Frederiek, Tjin-A-Ton, Manuel L.R., Valkenburg-van Iersel, Liselot B.J., van Voorthuizen, Theo, de Vos-Geelen, Judith, Vulink, Annelie J.E., J van de Wouw, Agnès, Hamers, Patricia A.H., Vink, Geraldine R., Elferink, Marloes A.G., Stellato, Rebecca K., Dijksterhuis, Willemieke P.M., Punt, Cornelis J.A., Koopman, Miriam, and May, Anne M.
- Published
- 2022
- Full Text
- View/download PDF
3. Trastuzumab Resistance in Patients With HER2-Positive Advanced Breast Cancer: Results From the SONABRE Registry
- Author
-
Ibragimova, Khava I.E., primary, Geurts, Sandra M.E., additional, Laczkó, Dávid, additional, Meegdes, Marissa, additional, Erdkamp, Frans, additional, Heijns, Joan B., additional, Tol, Jolien, additional, Vriens, Birgit E.P.J., additional, Aaldering, Kirsten N.A., additional, Dercksen, Marcus W., additional, Pepels, Manon J.A.E., additional, Peters, Natascha A.J.B., additional, van de Winkel, Linda M.H., additional, van de Wouw, Agnes J., additional, de Fallois, Aude, additional, van Kats, Maartje A.C.E., additional, and Tjan-Heijnen, Vivianne C.G., additional
- Published
- 2023
- Full Text
- View/download PDF
4. The prognostic impact of BMI in patients with HR+/HER2- advanced breast cancer: a study of the SONABRE registry
- Author
-
Lammers, Senna W.M., primary, Thurisch, Hannah, additional, Vriens, Ingeborg J.H., additional, Meegdes, Marissa, additional, Engelen, Sanne M.E., additional, Erdkamp, Frans L.G., additional, Dercksen, M. Wouter, additional, Vriens, Birgit E.P.J., additional, Aaldering, Kirsten N.A., additional, Pepels, Manon J.A.E., additional, de Winkel, Linda M.H. van, additional, Peters, Natascha A.J.B., additional, Tol, Jolien, additional, Heijns, Joan B., additional, de Wouw, Agnes J. van, additional, Teeuwen, Nathalie J.A., additional, Geurts, Sandra M.E., additional, and Tjan-Heijnen, Vivianne C.G., additional
- Published
- 2023
- Full Text
- View/download PDF
5. Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry
- Author
-
Meegdes, Marissa, primary, Geurts, Sandra M.E., additional, Erdkamp, Frans L.G., additional, Dercksen, M. Wouter, additional, Vriens, Birgit E.P.J., additional, Aaldering, Kirsten N.A., additional, Pepels, Manon J.A.E., additional, van de Winkel, Linda M.H., additional, Peters, Natascha A.J.B., additional, Tol, Jolien, additional, Heijns, Joan B., additional, van de Wouw, Agnes J., additional, de Fallois, Aude J.O., additional, van Kats, Maartje A.C.E., additional, and Tjan-Heijnen, Vivianne C.G., additional
- Published
- 2023
- Full Text
- View/download PDF
6. Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS)
- Author
-
Hamers, Patricia A.H., primary, Vink, Geraldine R., additional, Elferink, Marloes A.G., additional, Stellato, Rebecca K., additional, Dijksterhuis, Willemieke P.M., additional, Punt, Cornelis J.A., additional, Koopman, Miriam, additional, May, Anne M., additional, Beerepoot, Laurens V., additional, Creemers, Geert-Jan, additional, van Cruijsen, Hester, additional, de Groot, Jan Willem B., additional, van Halteren, Henk K., additional, Helgason, Helgi H., additional, Hendriks, Mathijs P., additional, Hoekstra, Ronald, additional, van Huis-Tanja, Lieke H., additional, Kapiteijn, Ellen, additional, Los, Maartje, additional, van Meerten, Esther, additional, Peters, Natascha A.J.B., additional, Pruijt, Johannes F.M., additional, van Ufford-Mannesse, Patricia Quarles, additional, Sie, Mark P.S., additional, Sommeijer, Dirkje W., additional, Spierings, Leontine E.A.M.M., additional, Terheggen, Frederiek, additional, Tjin-A-Ton, Manuel L.R., additional, Valkenburg-van Iersel, Liselot B.J., additional, van Voorthuizen, Theo, additional, de Vos-Geelen, Judith, additional, Vulink, Annelie J.E., additional, and J van de Wouw, Agnès, additional
- Published
- 2022
- Full Text
- View/download PDF
7. Physical Activity Is Associated with Improved Overall Survival among Patients with Metastatic Colorectal Cancer
- Author
-
Smit, Karel C., Derksen, Jeroen W.G., Beets, Geerard L.O., Belt, Eric J.Th, Berbée, Maaike, Coene, Peter Paul L.O., Van Cruijsen, Hester, Davidis, Marjan A., Dekker, Jan Willem T., Van Dodewaard-De Jong, Joyce M., Haringhuizen, Annebeth W., Helgason, Helgi H., Hendriks, Mathijs P., Hoekstra, Ronald, De Hingh, Ignace H.J.T., Ijzermans, Jan N.M., Janssen, Johan J.B., Konsten, Joop L.M., Los, Maartje, Mekenkamp, Leonie J.M., Nieboer, Peter, Peeters, Koen C.M.J., Peters, Natascha A.J.B., Pruijt, Hans J.F.M., Van Ufford-Mannesse, Patricia Quarles, Rietbroek, Ron C., Schiphorst, Anandi H.W., Van Der Velden, Arjan Schouten, Schrauwen, Ruud W.M., Sie, Mark P.S., Sommeijer, Dirkje W., Sonneveld, Dirk J.A., Stockmann, Hein B.A.C., Tent, Marleen, Terheggen, Frederiek, Tjin-A-Ton, Manuel L.R., Valkenburg-Van Iersel, Liselot, Van Der Velden, Ankie M.T., Vles, Wouter J., Van Voorthuizen, Theo, Wegdam, Johannes A., De Wilt, Johannes H.W., Koopman, Miriam, May, Anne M., Smit, Karel C., Derksen, Jeroen W.G., Beets, Geerard L.O., Belt, Eric J.Th, Berbée, Maaike, Coene, Peter Paul L.O., Van Cruijsen, Hester, Davidis, Marjan A., Dekker, Jan Willem T., Van Dodewaard-De Jong, Joyce M., Haringhuizen, Annebeth W., Helgason, Helgi H., Hendriks, Mathijs P., Hoekstra, Ronald, De Hingh, Ignace H.J.T., Ijzermans, Jan N.M., Janssen, Johan J.B., Konsten, Joop L.M., Los, Maartje, Mekenkamp, Leonie J.M., Nieboer, Peter, Peeters, Koen C.M.J., Peters, Natascha A.J.B., Pruijt, Hans J.F.M., Van Ufford-Mannesse, Patricia Quarles, Rietbroek, Ron C., Schiphorst, Anandi H.W., Van Der Velden, Arjan Schouten, Schrauwen, Ruud W.M., Sie, Mark P.S., Sommeijer, Dirkje W., Sonneveld, Dirk J.A., Stockmann, Hein B.A.C., Tent, Marleen, Terheggen, Frederiek, Tjin-A-Ton, Manuel L.R., Valkenburg-Van Iersel, Liselot, Van Der Velden, Ankie M.T., Vles, Wouter J., Van Voorthuizen, Theo, Wegdam, Johannes A., De Wilt, Johannes H.W., Koopman, Miriam, and May, Anne M.
- Abstract
Regular physical activity (PA) is associated with improved overall survival (OS) in stage I-III colorectal cancer (CRC) patients. This association is less defined in patients with metastatic CRC (mCRC). We therefore conducted a study in mCRC patients participating in the Prospective Dutch Colorectal Cancer cohort. PA was assessed with the validated SQUASH questionnaire, filled-in within a maximum of 60 days after diagnosis of mCRC. PA was quantified by calculating Metabolic Equivalent Task (MET) hours per week. American College of Sports and Medicine (ACSM) PA guideline adherence, tertiles of moderate to vigorous PA (MVPA), and sport and leisure time MVPA (MVPA-SL) were assessed as well. Vital status was obtained from the municipal population registry. Cox proportional-hazards models were used to study the association between PA determinants and all-cause mortality adjusted for prognostic patient and treatment-related factors. In total, 293 mCRC patients (mean age 62.9±10.6 years, 67% male) were included in the analysis. Compared to low levels, moderate and high levels of MET-hours were significantly associated with longer OS (fully adjusted hazard ratios: 0.491, (95% CI 0.299-0.807, p value=0.005) and 0.485 (95% CI 0.303-0.778, p value=0.003), respectively), as were high levels of MVPA (0.476 (95% CI 0.278-0.816, p value=0.007)) and MVPA-SL (0.389 (95% CI 0.224-0.677, p value<0.001)), and adherence to ACSM PA guidelines compared to non-adherence (0.629 (95% CI 0.412-0.961, p value=0.032)). The present study provides evidence that higher PA levels at diagnosis of mCRC are associated with longer OS.
- Published
- 2022
8. Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels:a proof-of-concept study
- Author
-
Tullemans, Bibian M.E., Brouns, Sanne L.N., Swieringa, Frauke, Sabrkhany, Siamack, van den Berkmortel, Franchette W.P.J., Peters, Natascha A.J.B., de Bruijn, Peter, Koolen, Stijn L.W., Heemskerk, Johan W.M., Aarts, Maureen J.B., Kuijpers, Marijke J.E., Tullemans, Bibian M.E., Brouns, Sanne L.N., Swieringa, Frauke, Sabrkhany, Siamack, van den Berkmortel, Franchette W.P.J., Peters, Natascha A.J.B., de Bruijn, Peter, Koolen, Stijn L.W., Heemskerk, Johan W.M., Aarts, Maureen J.B., and Kuijpers, Marijke J.E.
- Abstract
Background: Tyrosine kinase inhibitors (TKIs), such as sunitinib, are used for cancer treatment, but may also affect platelet count and function with possible hemostatic consequences. Here, we investigated whether patient treatment with the TKI sunitinib affected quantitative and qualitative platelet traits as a function of the sunitinib level and the occurrence of bleeding. Methods: Blood was collected from 20 metastatic renal cell carcinoma (mRCC) patients before treatment, and at 2 weeks, 4 weeks and 3 months after sunitinib administration. We measured blood cell counts, platelet aggregation, and concentrations of sunitinib as well as its N-desethyl metabolite in plasma, serum and isolated platelets. Progression of disease (PD) and bleeding were monitored after 3 months. Results: In sunitinib-treated mRCC patients, concentrations of (N-desethyl-)sunitinib in plasma and serum were highly correlated. In the patients’ platelets the active metabolite levels were relatively increased as compared to sunitinib. On average, a sustained reduction in platelet count was observed on-treatment, which was significantly related to the inhibitor levels in plasma/serum. Principal component and correlational analysis showed that the (N-desethyl-)sunitinib levels in plasma/serum were linked to a reduction in both platelet count and collagen-induced platelet aggregation. The reduced aggregation associated in part with reported bleeding, but did not correlate to PD. Conclusion: The sunitinib-induced reduction in quantitative and qualitative platelet traits may reflect the effective sunitinib levels in the patient. These novel results may serve as a proof-of-principle for other TKI-related drugs, where both platelet count and functions are affected, which could be used for therapeutic drug monitoring.
- Published
- 2022
9. Trajectories of health-related quality of life and psychological distress in patients with colorectal cancer: A population-based study
- Author
-
Qaderi, Seyed M., primary, van der Heijden, Joost A.G., additional, Verhoeven, Rob H.A., additional, de Wilt, Johannes H.W., additional, Custers, Jose A.E., additional, Beets, Geerard L., additional, Belt, Eric J.Th., additional, Berbée, Maaike, additional, Beverdam, Frederique H., additional, Blankenburgh, Ruud, additional, Coene, Peter Paul L.O., additional, de Groot, Jan Willem B., additional, de Hingh, Ignace H.J.T., additional, de Vos, Aad I., additional, Dekker, Jan Willem T., additional, Erdkamp, Frans L.G., additional, Haringhuizen, Annebeth W., additional, Helgason, Helgi H., additional, Hendriks, Mathijs P., additional, Hoekstra, Ronald, additional, Ijzermans, Jan N.M., additional, Jansen, Jan, additional, Kloppenberg, Frank W.H., additional, Los, Maartje, additional, Meijerink, Martijn R., additional, Mekenkamp, Leonie J.M., additional, Nieboer, Peter, additional, Peeters, Koen C.M.J., additional, Peters, Natascha A.J.B., additional, Polée, Marco B., additional, Pruijt, Johannes F.M., additional, van Ufford-Mannesse, Patricia Quarles, additional, Rietbroek, Ron C., additional, Schiphorst, Anandi H.W., additional, van der Velden, Arjan Schouten, additional, Schrauwen, Ruud W.M., additional, Sie, Mark P.S., additional, Simkens, Lieke, additional, Sommeijer, Dirkje W., additional, Sonneveld, Dirk J.A., additional, Spierings, Leontine E.A., additional, Stockmann, Hein B.A.C., additional, Talsma, Koen, additional, ten Tije, Albert J., additional, Terheggen, Frederiek, additional, Tjin-A-Ton, Manuel L.R., additional, Valkenburg-van Iersel, Liselot B.J., additional, van Cruijsen, Hester, additional, Velden, Ankie M.T. van der, additional, van Dodewaard-de Jong, Joyce M., additional, van Lent, Anja U.G., additional, van Voorthuizen, Theo, additional, Vermaas, Maarten, additional, Vles, Wouter J., additional, Vogelaar, Jeroen F.J., additional, and Zimmerman, David D.E., additional
- Published
- 2021
- Full Text
- View/download PDF
10. Work Ability in Patients With Stage I to IV Colon Cancer: Results of the Dutch Prospective Colorectal Cancer Cohort
- Author
-
Franken, Mira D., Vink, Geraldine, van Grevenstein, Wilhelmina M.U., Verkooijen, Helena M., Punt, Cornelis J.A., Koopman, Miriam, May, Anne M., Beets, Geerard L., Belt, Eric J.Th., Berbée, Maaike, Beverdam, Frederique H., Blankenburgh, Ruud, Coene, Peter Paul L.O., de Groot, Jan Willem B., de Hingh, Ignace H.J.T., de Vos, Aad I., de Wilt, Johannes H.W., Dekker, Jan Willem T., Erdkamp, Frans L.G., Haringhuizen, Annebeth W., Helgason, Helgi H., Hendriks, Mathijs P., Hoekstra, Ronald, Ijzermans, Jan N.M., Jansen, Jan, Kloppenberg, Frank W.H., Los, Maartje, Meijerink, Martijn R., Mekenkamp, Leonie J.M., Nieboer, Peter, Peeters, Koen C.M.J., Peters, Natascha A.J.B., Pruijt, Johannes F.M., van Ufford-Mannesse, Patricia Quarles, Rietbroek, Ron C., Schiphorst, Anandi H.W., Sie, Mark P.S., Simkens, Lieke H.J., Sommeijer, Dirkje W., Spierings, Leontine E.A., Stockmann, Hein B.A.C., ten Tije, Albert J., Terheggen, Frederiek, Tjin-A-Ton, Manuel L.R., Valkenburg-van Iersel, Liselot B.J., van Cruijsen, Hester, van der Velden, Ankie M.T., van Dodewaard-de Jong, Joyce M., van Lent, Anja U.G., Voorthuizen, Theo van, Vermaas, Maarten, Vles, Wouter J., Vogelaar, Jeroen F.J., and Zimmerman, David D.E.
- Published
- 2023
- Full Text
- View/download PDF
11. Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): Study protocol for a trial within a cohort study
- Author
-
Schraa, S. J., Van Rooijen, K. L., Van Der Kruijssen, D. E.W., Rubio Alarcón, C., Phallen, J., Sausen, M., Simmons, J., Coupé, V. M.H., Van Grevenstein, W. M.U., Elias, S., Verkooijen, H. M., Laclé, M. M., Bosch, L. J.W., Van Den Broek, D., Meijer, G. A., Velculescu, V. E., Fijneman, R. J.A., Vink, G. R., Koopman, M., Dunker, Mich S., Lutke Holzik, Martijn F., Hoekstra, Ronald, Sommeijer, Dirkje W., Van Der Bilt, Jarmila D.W., Consten, Esther C.J., Cirkel, Geert A., Burghgraef, Thijs A., Van Der Schans, Emma M., Nieboer, Peter, Rietbroek, Ron C., Dekker, Jan Willem T., Verschoor, Arjan J., Talsma, Koen A.K., Brosens, Rebecca P.M., Helgason, Helgi H., Marinelli, Andreas W.K.S., De Hingh, Ignace H.J.T., Oldenhuis, Corina N., Jansen, Jan, Van Halteren, Henk K., Stockmann, Hein B.A.C., Beeker, Aart, Bosscha, Koop, Pruijt, Hans F.M., Spierings, Leontine E.A.M.M., Valkenburg-Van Iersel, Liselot B.J., Vles, Wouter J., De Jongh, Felix E., Van Cruijsen, Hester, Heikens, Joost T., Zimmerman, David D.E., Van Alphen, Robert J., Schiphorst, Anandi H.W., Van Leeuwen-Snoeks, Lobke L., Vogelaar, Jeroen F.J., Peters, Natascha A.J.B., Epidemiology and Data Science, APH - Methodology, CCA - Cancer Treatment and quality of life, Pathology, Internal medicine, Orthopedic Surgery and Sports Medicine, VU University medical center, Surgery, Robotics and image-guided minimally-invasive surgery (ROBOTICS), RS: NUTRIM - R3 - Respiratory & Age-related Health, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, MUMC+: MA Medische Oncologie (9), Medical Biology, Nephrology, and Oncology
- Subjects
0301 basic medicine ,Oncology ,Male ,Cancer Research ,Neoplasm, Residual ,Colorectal cancer ,Cost-Benefit Analysis ,COLORECTAL-CANCER ,Circulating Tumor DNA ,Study Protocol ,0302 clinical medicine ,RESIDUAL DISEASE ,Antineoplastic Combined Chemotherapy Protocols ,Clinical endpoint ,Prospective Studies ,Colectomy ,Netherlands ,Randomized Controlled Trials as Topic ,RISK ,education.field_of_study ,RANDOMIZED CONTROLLED-TRIAL ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Colon cancer ,Oxaliplatin ,Chemotherapy, Adjuvant ,CELL-FREE DNA ,030220 oncology & carcinogenesis ,Colonic Neoplasms ,Practice Guidelines as Topic ,SURVIVAL ,Female ,medicine.drug ,Cohort study ,Adult ,medicine.medical_specialty ,Population ,TwiCs ,lcsh:RC254-282 ,Disease-Free Survival ,LEUCOVORIN ,Capecitabine ,03 medical and health sciences ,Internal medicine ,Genetics ,medicine ,Biomarkers, Tumor ,Humans ,RECURRENCE ,education ,Neoplasm Staging ,Intention-to-treat analysis ,business.industry ,Liquid Biopsy ,ctDNA ,Patient Acceptance of Health Care ,medicine.disease ,Minimal residual disease ,FLUOROURACIL ,Adjuvant chemotherapy ,030104 developmental biology ,Quality of Life ,Neoplasm Recurrence, Local ,business ,Follow-Up Studies - Abstract
Background Accurate detection of patients with minimal residual disease (MRD) after surgery for stage II colon cancer (CC) remains an urgent unmet clinical need to improve selection of patients who might benefit form adjuvant chemotherapy (ACT). Presence of circulating tumor DNA (ctDNA) is indicative for MRD and has high predictive value for recurrent disease. The MEDOCC-CrEATE trial investigates how many stage II CC patients with detectable ctDNA after surgery will accept ACT and whether ACT reduces the risk of recurrence in these patients. Methods/design MEDOCC-CrEATE follows the ‘trial within cohorts’ (TwiCs) design. Patients with colorectal cancer (CRC) are included in the Prospective Dutch ColoRectal Cancer cohort (PLCRC) and give informed consent for collection of clinical data, tissue and blood samples, and consent for future randomization. MEDOCC-CrEATE is a subcohort within PLCRC consisting of 1320 stage II CC patients without indication for ACT according to current guidelines, who are randomized 1:1 into an experimental and a control arm. In the experimental arm, post-surgery blood samples and tissue are analyzed for tissue-informed detection of plasma ctDNA, using the PGDx elio™ platform. Patients with detectable ctDNA will be offered ACT consisting of 8 cycles of capecitabine plus oxaliplatin while patients without detectable ctDNA and patients in the control group will standard follow-up according to guideline. The primary endpoint is the proportion of patients receiving ACT when ctDNA is detectable after resection. The main secondary outcome is 2-year recurrence rate (RR), but also includes 5-year RR, disease free survival, overall survival, time to recurrence, quality of life and cost-effectiveness. Data will be analyzed by intention to treat. Discussion The MEDOCC-CrEATE trial will provide insight into the willingness of stage II CC patients to be treated with ACT guided by ctDNA biomarker testing and whether ACT will prevent recurrences in a high-risk population. Use of the TwiCs design provides the opportunity to randomize patients before ctDNA measurement, avoiding ethical dilemmas of ctDNA status disclosure in the control group. Trial registration Netherlands Trial Register: NL6281/NTR6455. Registered 18 May 2017, https://www.trialregister.nl/trial/6281
- Published
- 2020
12. Bowel Perforation After Radiotherapy in a Patient Receiving Sorafenib
- Author
-
Peters, Natascha A.J.B., primary, Richel, Dick J., additional, Verhoeff, Joost J.C., additional, and Stalpers, Lukas J.A., additional
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.